Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
40.83
-0.14 (-0.34%)
At close: Feb 11, 2026, 4:00 PM EST
40.04
-0.79 (-1.93%)
After-hours: Feb 11, 2026, 7:09 PM EST
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $207.64M in the quarter ending September 30, 2025, with 13.75% growth. This brings the company's revenue in the last twelve months to $741.17M, up 17.92% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$741.17M
Revenue Growth
+17.92%
P/S Ratio
5.72
Revenue / Employee
$1,482,344
Employees
500
Market Cap
4.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.05B |
| Amicus Therapeutics | 598.70M |
| TG Therapeutics | 531.90M |
| ADMA Biologics | 488.56M |
| CRISPR Therapeutics AG | 38.34M |
| Arcellx | 35.90M |
| NewAmsterdam Pharma Company | 35.24M |
| CG Oncology | 2.17M |
CORT News
- 2 days ago - CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 2 days ago - Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT - PRNewsWire
- 7 days ago - Allspring Emerging Growth Fund Q4 2025 Performance Review - Seeking Alpha
- 7 days ago - Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman - GlobeNewsWire
- 12 days ago - Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing - Business Wire
- 12 days ago - Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application - GlobeNewsWire
- 12 days ago - Corcept shares tumble after FDA letter reveals warnings before drug rejection - Reuters
- 12 days ago - Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses - GlobeNewsWire